Here we report the characterization of MEN1611 in comparison with other PI3K inhibitors in terms of PI3K isoforms inhibition profile and the investigation of its efficacy as single agent and in combination with trastuzumab in several in vivo xenograft models of HER2 + breast cancers. This evidence concerns the gene PIK3CD and breast carcinoma.